Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluocinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.75 |
| ▸ | LMNA | P02545 | 7/20 | 0.75 |
| ▸ | PGR | P06401 | 5/20 | 0.75 |
| ▸ | AR | P10275 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluocinonide SCHEMBL28122375 | 1.00 | HIF1A (0.75) | HIF1ALMNANR3C1PGRAR | |
| Fluocinolone Acetonide SCHEMBL5501859 | 0.94 | HIF1A (0.77) | HIF1ALMNANR3C1PGRAR | |
| Fluocinonide SCHEMBL11325670 | 0.93 | HIF1A (0.82) | HIF1ALMNANR3C1PGRAR | |
| Amcinonide SCHEMBL16093940 | 0.89 | CYP3A4 (0.85) | HIF1ALMNANR3C1PGRAR | |
| Amcinonide SCHEMBL13723413 | 0.89 | HIF1A (0.70) | HIF1ALMNANR3C1PGRAR | |
| Fluocinonide SCHEMBL11596245 | 0.88 | NR3C1 (0.68) | HIF1ALMNANR3C1PGRAR | |
| Triamcinolone Acetonide SCHEMBL28103100 | 0.88 | CYP3A4 (0.87) | HIF1ALMNANR3C1PGRAR | |
| Fluocinonide SCHEMBL28089918 | 0.88 | NR3C1 (0.94) | HIF1ALMNANR3C1PGRAR | |
| Fluocinonide SCHEMBL2863286 | 0.88 | HIF1A (0.58) | HIF1ALMNANR3C1PGRAR | |
| SCHEMBL15975096 | 0.87 | HIF1A (0.87) | HIF1ALMNANR3C1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3284459-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | MOBERG PHARMA AB (SE) | 2021-01-06 | — | — | EP | disclosed |
| US-20180221358-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | ONCOZENGE AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-9956211-B2 | Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat | MOBERG PHARMA AB (SE) | 2018-05-01 | — | — | US | disclosed |
| EP-3284459-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | Moberg Pharma AB (SE) | 2018-02-21 | — | — | EP | disclosed |
| EP-3173069-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | Moberg Pharma AB (SE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2701681-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | MOBERG PHARMA AB (SE) | 2016-10-19 | — | — | EP | disclosed |
| US-20140296293-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | ORACAIN II APS (DK) | 2014-10-02 | — | — | US | disclosed |
| EP-2701681-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | Oracain II ApS (DK) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012146763-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | ORACAIN II APS (DK) | 2012-11-01 | — | — | WO | disclosed |
| US-8236348-B2 | Throat lozenges and chewing gums containing an aqueous matrix of ethyl cellulose and an essential oil; cold remedies, sore throats, weight loss, smoking cessation | BENNES, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2242484-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LUBRICATING AN ORAL CAVITY | Bennes, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009042968-A1 | SUSTAINED RELEASE DOSAGE FORMS FOR DELIVERY OF AGENTS TO AN ORAL CAVITY OF A USER | BENNES, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042969-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LUBRICATING AN ORAL CAVITY | BENNES, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090081291-A1 | Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User | BENNES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090081294-A1 | Sustained release dosage form for lubricating an oral cavity | BENNES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1589952-B1 | LONG-LASTING, FLAVORED DOSAGE FORMS FOR SUSTAINED RELEASE OF BENEFICIAL AGENTS WITHIN THE MOUTH | BENNES INC (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1589952-A2 | LONG-LASTING, FLAVORED DOSAGE FORMS FOR SUSTAINED RELEASE OF BENEFICIAL AGENTS WITHIN THE MOUTH | Bennes, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040247669-A1 | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth | BENNES, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004070017-A2 | LONG-LASTING, FLAVORED DOSAGE FORMS FOR SUSTAINED RELEASE OF BENEFICIAL AGENTS WITHIN THE MOUTH | BENNES, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040151771-A1 | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth | BENNES, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221358-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | MB, SSB, MBNL1 | NR3C1 2747/4885HIF1A 918/4885LMNA 2542/4885 |
| US-20140296293-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT | MB, SSB, MBNL1 | NR3C1 2747/4885HIF1A 918/4885LMNA 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.